In the present study, we combined the results of different CTC isolation methods, (a) an EpCAM-independent method (Ficoll) [19,30] and (b) an EpCAM-dependent method [35,36], in association with two different detection methods, (a) immunofluorescence analysis [19,30] and (b) molecular analysis [21], for a more holistic approach regarding the expression status of the above biomarkers in the CTCs of prostate cancer patients. The gene discussed is EPCAM; the disease is Familial prostate cancer.